NOVAVAX FILES $100 MLN EQUITY SHELF OFFERING

Biotech company Novavax Inc. on Wednesday said it may periodically sell up to $100 million in common and preferred stock and warrants. The company said it plans to use the proceeds for general corporate purposes, which may include clinical development of avian and seasonal flu vaccines, internal research and development, expansion of facilities and general working capital.

Reuters (http://today.reuters.com/investing/financeArticle.aspx?type=bondsNews&storyID=2005-12-21T213102Z_01_WBT004422_RTRIDST_0_HEALTH-NOVAVAX-SHELF-URGENT.XML)